DVA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
DVA is a good buy for a beginner long-term investor with $50,000-$100,000 available, and I would take the buy now rather than wait. The stock has fresh fundamental momentum from a strong Q1 2026 earnings beat, multiple analyst upgrades, and improving price targets, while the trend remains bullish. The main reason to buy now is that the company is showing real earnings and revenue growth, and Wall Street is clearly revising expectations higher.
DVA is in a strong uptrend. MACD is positive and expanding, SMA_5 is above SMA_20 and SMA_200, which confirms bullish structure. However, RSI_6 at 92.387 shows the stock is very overbought, so the move has already run hard. Price at 197 is near resistance at R2 199.092 and above R1 187.509, meaning momentum is still strong but short-term upside may be less explosive from here. The technical picture supports buying for long-term strength, not chasing for a short-term dip.
["Q1 2026 revenue of $3.4155B beat expectations and grew 5.96% YoY.", "Net income rose 21.25% YoY and EPS increased 43.50% YoY to 2.87.", "Gross margin improved to 26.22%, up 4.67% YoY.", "Deutsche Bank upgraded DVA to Buy and raised target to $220 after the Q1 report.", "UBS raised its target to $235 and kept a Buy rating.", "Strong post-earnings momentum pushed the stock to an all-time high.", "Options activity is skewed toward calls, reinforcing bullish sentiment."]
["RSI is extremely overbought, so short-term upside may be stretched.", "Hedge funds are selling heavily, with selling increasing 6939.07% over the last quarter.", "Barclays remains only Equal Weight despite raising its target, which shows some caution.", "The stock is already trading near resistance, limiting immediate upside from a technical perspective."]
Latest quarter: Q1 2026. DaVita delivered solid growth across the board. Revenue increased to $3.4155B, up 5.96% YoY. Net income rose to $197.53M, up 21.25% YoY. EPS climbed to $2.87, up 43.50% YoY. Gross margin improved to 26.22%, up 4.67% YoY. This is a strong quarterly report with improving profitability and earnings leverage, which supports a long-term bullish case.
Recent analyst trend is clearly positive. Deutsche Bank upgraded DVA to Buy from Hold and lifted the target to $220 from $126 after Q1, citing strong revenue per treatment and treatment growth. UBS also raised its target to $235 and kept a Buy rating. Barclays raised its target to $194 from $158 but stayed at Equal Weight, showing some divide in conviction. Overall, Wall Street is leaning bullish: the pros see improving operating momentum and higher fair value estimates, while the main caution is that not every firm is fully aligned on upside magnitude. No recent politician or influential figure trading data was available. No congress trading data was available.
